ALTAltimmune, Inc.vs its industry peers
A metric-by-metric comparison of Altimmune, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALTThis | $633M#8 | — | 1.3x#3 | 15442.8x#12 | 105.0%#6 | 7.3%#11 | -230461.0%#13 | -18.6%#9 | -21.1%#3 | — | -10.6%#13 | — |
| MNPR | $699M#1 | — | 5.3x#10 | — | — | 12.0%#10 | — | -10.5%#7 | — | — | 83.0%#6 | — |
| IRWD | $695M#2 | 5.3x#2 | — | 2.3x#3 | -15.7%#9 | 2629.5%#1 | 33.3%#2 | — | 42.6%#1 | — | 224.7%#1 | — |
| ZVRA | $692M#3 | 12.5x#4 | 3.2x#8 | 6.5x#5 | 350.9%#3 | 178.9%#4 | -59.1%#5 | 38.2%#1 | — | — | 60.7%#7 | — |
| NGNE | $678M#4 | — | 3.1x#7 | — | -100.0%#13 | -20.2%#12 | — | -41.6%#11 | — | — | 94.9%#5 | — |
| VSTM | $656M#5 | — | 13.1x#11 | 21.2x#8 | 209.1%#5 | -60.3%#14 | -550.3%#9 | -419.1%#13 | — | — | -20.6%#14 | — |
| CBIO | $647M#6 | — | 4.0x#9 | 59.7x#9 | — | 306.4%#3 | -1407.5%#11 | 0.1%#4 | — | — | 39.4%#9 | — |
| PHAT | $636M#7 | — | — | 3.6x#4 | 216.9%#4 | 33.8%#9 | -91.4%#6 | — | — | 4#1 | -28.4%#15 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#7 | 76.2%#5 | -111.0%#7 | 22.5%#3 | — | — | 110.5%#4 | — |
| CRMD | $610M#9 | 3.6x#1 | 1.3x#2 | 2.0x#1 | 617.0%#2 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | — | — |
| CTMX | $594M#12 | — | 2.0x#4 | 7.8x#6 | -44.8%#11 | -154.5%#16 | -29.3%#3 | -5.7%#5 | -7.8%#2 | — | 38.7%#10 | — |
| STTK | $594M#11 | — | 2.8x#6 | 594.2x#11 | -82.5%#12 | 35.3%#7 | -5150.8%#12 | -23.1%#10 | — | — | 177.9%#2 | — |
| AQST | $598M#10 | — | — | 13.4x#7 | -22.6%#10 | -89.8%#15 | -159.5%#8 | — | — | — | -2.2%#12 | — |
| ANNX | — | — | — | — | — | -49.6%#13 | — | -111.1%#12 | — | — | 48.5%#8 | — |
| ARVN | $530M#13 | 31.2x#5 | 0.9x#1 | 2.0x#2 | -0.3%#8 | 59.3%#6 | -45.1%#4 | -14.4%#8 | -25.3%#4 | — | 6.2%#11 | — |
| OVID | $520M#14 | — | 2.5x#5 | 71.8x#10 | 1181.3%#1 | 34.1%#8 | -585.2%#10 | -8.3%#6 | — | — | 126.8%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice